Florent Grange
A5059800915- Cutaneous lymphoproliferative disorders research
- Cutaneous Melanoma Detection and Management
- Lymphoma Diagnosis and Treatment
- Nonmelanoma Skin Cancer Studies
- Melanoma and MAPK Pathways
- CAR-T cell therapy research
- Cancer Immunotherapy and Biomarkers
- Fungal Infections and Studies
- Cancer and Skin Lesions
- Hedgehog Signaling Pathway Studies
- Nail Diseases and Treatments
- Autoimmune Bullous Skin Diseases
- Immunotherapy and Immune Responses
- CNS Lymphoma Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- Allergic Rhinitis and Sensitization
- T-cell and Retrovirus Studies
- Skin Protection and Aging
- Protein Tyrosine Phosphatases
- Polyomavirus and related diseases
- Colorectal Cancer Treatments and Studies
- melanin and skin pigmentation
- Cancer Genomics and Diagnostics
- Urticaria and Related Conditions
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
Centre Hospitalier de Valence
2021-2024
Université de Reims Champagne-Ardenne
2015-2024
Hôpital Robert-Debré
2014-2024
Centre Hospitalier Universitaire de Reims
2015-2024
Lymphoma Study Association
2013-2024
Inserm
1993-2023
Oxfam
2023
Liechtenstein Institute
2023
John Wiley & Sons (United States)
2023
Hudson Institute
2023
The BRAF inhibitors vemurafenib and dabrafenib have shown efficacy as monotherapies in patients with previously untreated metastatic melanoma V600E or V600K mutations. Combining the MEK inhibitor trametinib, compared alone, enhanced antitumor activity this population of patients.In open-label, phase 3 trial, we randomly assigned 704 a V600 mutation to receive either combination (150 mg twice daily) trametinib (2 once (960 orally first-line therapy. primary end point was overall survival.At...
To evaluate the efficacy and safety of cetuximab, a monoclonal antibody that inhibits epidermal growth factor receptor (EGFR), as first-line monotherapy in patients with unresectable squamous cell carcinoma skin (SCCS).Thirty-six received cetuximab (initial dose 400 mg/m(2) followed by subsequent weekly doses 250 mg/m(2)) for at least 6 weeks 48-week follow-up. The primary end point was disease control rate (DCR) (according to Response Evaluation Criteria Solid Tumors [RECIST] criteria)....
Therapeutic monoclonal anti-cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) antibodies are associated with immune-mediated enterocolitis. The aim of this study was to provide a detailed description entity. We included patients endoscopic signs inflammation after anti-CTLA-4 infusions for cancer treatment. Other causes enterocolitis were excluded. Clinical, biological and data recorded. A single pathologist reviewed biopsies colectomy specimens from 27 patients. Patients without...
Treatment options are limited for patients with recurrent and/or metastatic (R/M) cutaneous squamous cell carcinoma (cSCC); mortality rates exceed 70% in distant metastases. Here, we present the first interim analysis of R/M cSCC cohort from 2-cohort-locally advanced and R/M-phase II KEYNOTE-629 study.
PURPOSE To evaluate first-line pembrolizumab monotherapy efficacy and safety in patients with unresectable cutaneous squamous cell carcinomas (CSCCs). PATIENTS AND METHODS Patients, predominantly men, their CSSCs’ immunohistochemically determined programmed death-ligand 1 (PD-L1) status (tumor proportion score threshold, 1%), received (200 mg every 3 weeks). The primary endpoint was the 39-patient cohort’s objective response rate at week 15 (ORR W15 ). Secondary objectives were best ORR,...
Pembrolizumab demonstrated clinically meaningful and durable antitumor activity with a manageable safety profile in recurrent/metastatic (R/M) cutaneous squamous cell carcinoma (cSCC).KEYNOTE-629 was global, open-label, nonrandomized, phase II trial of patients locally advanced (LA) or R/M cSCC conducted at 59 centers. Eligible received intravenous pembrolizumab 200 mg every 3 weeks for up to 35 cycles. Primary endpoint objective response rate (ORR), defined as the percentage complete (CR)...
PURPOSE: Most primary cutaneous B-cell lymphomas have an excellent prognosis. However, large (PCLBCLs) of the leg been recognized as a distinct entity with poorer prognosis in European Organization for Research and Treatment Cancer (EORTC) classification. This distinction on basis site has debated. Our aim was to identify independent prognostic factors multicenter series PCLBCL. PATIENTS AND METHODS: The clinical histologic data 145 patients PCLBCL were evaluated. According EORTC...
To describe clinicopathologic features and to identify prognostic factors in a large series of primary cutaneous diffuse B-cell lymphoma, leg type (PCLBCL LT), as defined the recent World Health Organization-European Organization for Research Treatment Cancer classification lymphomas.Retrospective multicenter study from French Study Group on Cutaneous Lymphomas.Nineteen departments dermatology 10 regions France.Sixty patients with PCLBCL LT included registry Lymphomas.Age, sex, outcome,...
Blastic natural killer (NK) cell lymphoma (also termed CD4+CD56+ hematodermic neoplasm) is a recently described entity, with the first case reported in 1994. It was suggested initially that disease originates from NK cells. Since 1994, single cases and few small series have been published. In this review, data literature of 30 French Dutch study groups on cutaneous lymphomas are discussed. The major clinical, histopathologic, phenotypic aspects diagnostic criteria suggesting plasmacytoid...
The authors report 4 cases of cutaneous lymphoproliferation unusual by their histology and clinical presentation. Each presented with a history slow growing nodule on the ear. Despite indolent evolution, suggested high-grade lymphoma. All lesions consisted dense, diffuse proliferation monomorphous medium-sized T cells throughout dermis subcutis. There was no epidermotropism grenz zone clearly present in each case. tumor displayed irregular blastlike nuclei, small nucleoli clear chromatin had...
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare disease characterized by malignant proliferation of contingent blastic cell. This entity recognized mostly cutaneous spreading, or not having leukaemic component. The prognosis very poor.To study large cohort 90 patients with BPDCN, to define additional symptoms form correct diagnosis earlier, and manage such accordingly.We retrospectively reviewed BPDCN cases registered in the French Study Group on Cutaneous Lymphoma database...
Journal Article Blastic plasmacytoid dendritic cell neoplasm: is transplantation the treatment of choice? Get access S. Dalle, Dalle Department Dermatology, Université Claude Bernard Lyon 1, Hospices Civils de Lyon, INSERM U590, France Stéphane Service Dermatologie, Centre Hospitalier Lyon‐Sud, 16S Cherin du Grand Revoyer, 69495 Pierre‐Bérite, France. E‐mail: stephane.dalle@chu‐lyon.fr Search for other works by this author on: Oxford Academic Google Scholar M. Beylot‐Barry, Beylot‐Barry...
The activating mutation of MYD88 L265P is a frequent feature primary cutaneous diffuse large B-cell lymphoma, leg-type (PCLBCL-LT), reported in up to 69% the cases. Whether patients with display specific clinical and evolutive features has not been evaluated.To identify characteristics associated mutation, confirm its high prevalence, evaluate effect on prognosis PCLBCL-LT.A retrospective multicenter study was conducted using medical records from dermatology departments belonging French...
Objective: To investigate the diagnostic value of commercially available BP230 and BP180-NC16a enzyme-linked immunosorbent assays (ELISAs) in routine practice patients with bullous pemphigoid (BP).